

N A P R A

Annual Report 2002 • 2003

THE NATIONAL ASSOCIATION OF PHARMACY REGULATORY AUTHORITIES



Pharmacists in Canada providing care that consistently meets the highest possible standards

- Goal 1:** “Act as a national information clearinghouse and resource centre, and provide services to the member regulatory authorities in relation to all aspects of pharmacy regulation.”
- Goal 2:** “Represent, promote and facilitate, both nationally and internationally, the interests and activities of the member provincial regulatory authorities.”
- Goal 3:** “Oversee, coordinate and promote the activities of the national drug scheduling committee, and promote harmonization of the conditions of sale of drugs throughout Canada.”
- Goal 4:** “Develop model legislation and standards respecting the profession of pharmacy and pharmacies, and promote the harmonization of such legislation and standards.”

The Optimal Health of Canadians

Our products, services and policies reflect our commitment to achieving the highest possible standard of health for Canadians.

Respect for the Autonomy of each Member Pharmacy Regulatory Authority

We see our role as serving the Member Pharmacy Regulatory Authorities and taking actions that enhance and support their vision and goals.

Teamwork and Partnerships

We strive for synergy by working together as a team and forming strategic and tactical partnerships with our stakeholders.

Innovation and Creativity

We are driven to find new products, services and practices that will support the optimal health of Canadians.

Transparency and Accountability

The decisions, policies and regulations that we promote fully meet the needs and requirements of our members. We act in compliance with the guidance and counsel of the representatives from the Member Pharmacy Regulatory Authorities.

Strong Leadership and Effective Governance

We lead and govern our organization with high standards, integrity and committed stewardship.

THE NATIONAL ASSOCIATION OF PHARMACY REGULATORY AUTHORITIES

Our Vision “2005”

Our Corporate Goals

Our Shared Values



NAPRA Board of Directors and Staff 2003



From left to right:

Front Row:

Lois Cantin, Jeff May, Linda Lytle, Hugh Ellis, Barbara Wells

Back Row:

Louise Gaulin, Janet Bradshaw, Don Rowe, Ronald Guse, Ray Joubert, Bill Veniot, Jeannie Collins Beaudin, Greg Eberhart, Lt. Col Régis Vaillancourt., Paul Tibbo, Neila Auld, Susan Wedlake, Shawn Sandhu, Arlene Crane

Missing from photo:

Greg Burton, Jeannette Hall, Janet Zral

NAPRA Committees 2002-2003

Executive Committee

Hugh Ellis, President – New Brunswick Pharmaceutical Society

Lois Cantin, Vice-President – Manitoba Pharmaceutical Association (Chairman)

Jeff May, Past-President

Shawn Sandhu – College of Pharmacists of British Columbia

Barbara Wells, Executive Director

Council of Pharmacy Registrars of Canada (formerly the Inter-Provincial Regulatory Committee)

Linda Lytle, Chairman – College of Pharmacists of British Columbia

Ronald Guse, Vice-Chairman – Manitoba Pharmaceutical Association

Neila Auld – Prince Edward Island Pharmacy Board

Greg Eberhart – Alberta College of Pharmacists

Jeannette Hall – Government of the Northwest Territories

Ray Joubert – Saskatchewan Pharmaceutical Association

Don Rowe – Newfoundland Pharmaceutical Association

Lt. Col. Régis Vaillancourt – Canadian Armed Forces

Bill Veniot – New Brunswick Pharmaceutical Society

Susan Wedlake – Nova Scotia College of Pharmacists

Janet Zral – Government of the Yukon

National Drug Scheduling Advisory Committee (NDSAC)

Dr. Marilyn Caughlin, Chairman – Regina, Saskatchewan

Dr. Jeff Taylor, Vice-Chairman – Saskatoon, Saskatchewan

Dr. Mark Armstrong – Edmonton, Alberta

Dawn Frail – Halifax, Nova Scotia

Phil Hudson – Kitchener, Ontario

Dr. Larry Lynd – Hamilton, Ontario

Fred Rumpel – Edmonton, Alberta

Joan Sayer (Representing Consumers' Association of Canada)

National Advisory Committee on Licensing (NACL)

Neila Auld, Chairman – Prince Edward Island Pharmacy Board

Cathy Biggs – Alberta College of Pharmacists

Carson Collins – Newfoundland Pharmaceutical Association

Dawn Frail – Nova Scotia College of Pharmacists

Jeanne Eriksen – Saskatchewan Pharmaceutical Association

Scott McGibney – Manitoba Pharmaceutical Association

Dr. Brenda Osmond – College of Pharmacists of British Columbia

Bill Veniot – New Brunswick Pharmaceutical Society

National Advisory Committee on Pharmacy Practice (NACPP)

Ronald Guse, Chairman – Manitoba Pharmaceutical Association

Ron Elliott, Canadian Pharmacists Association

Cynthia Jackevicius, Canadian Society of Hospital Pharmacists

Carole Mckie, Canadian Society of Consultant Pharmacists (a Chapter of the American Society of Consultant Pharmacists)


Dr. Glen Pearson – Nova Scotia College of Pharmacists

Margot Priddle, Newfoundland Pharmaceutical Association

Deb Saltmarche, Canadian Association of Chain Drug Stores

Dr. Brenda Schuster – Saskatchewan Pharmaceutical Association

Tinka Von Keyserlingk – College of Pharmacists of British Columbia



National Advisory Committee on Pharmacy Operations (NACPO)

Janet Bradshaw, Chairman – Saskatchewan Pharmaceutical Association
Merv Blair – Alberta College of Pharmacists
Wally Kowalchuk – Prince Edward Island Pharmacy Board
Nancy Roberts – New Brunswick Pharmaceutical Society
Deb Saltmarche, Canadian Association of Chain Drug Stores
Tim Fleming, Canadian Association of Pharmacy Technicians
Shelley Stepanuk, Canadian Pharmacists Association

National Competency Based Standards of Practice Working Group

Neila Auld, Prince Edward Island
Carol Beveridge, Ontario
Cathy Biggs, Alberta
Rob Jaska, Manitoba
Eric Lee, Manitoba
Erin Mackenzie, Prince Edward Island
Andree Mallet, Yukon
John McNeil, Nova Scotia
Midge Monaghan, Ontario
Cathy Purvis, New Brunswick
Dr. Brenda Schuster, Saskatchewan
Zebrina Suleiman, Ontario
Lt. Col. Régis Vaillancourt, Ontario
Tinka von Keyserlingk, British Columbia

National Continuing Competence Program Core Steering Committee (NCCPCSC)

Ray Joubert, Chairman – Saskatchewan Pharmaceutical Association
Deb Barnhill, Canadian Council on Continuing Education in Pharmacy
Hugh Ellis – New Brunswick Pharmaceutical Society
Allan Greene – Prince Edward Island Pharmacy Board
Gary Groves – Saskatchewan Pharmaceutical Association
Doreen Leong – College of Pharmacists of British Columbia
Robert Stasyk – Alberta College of Pharmacists
Pat Trozzo – Manitoba Pharmaceutical Association
Susan Wedlake – Nova Scotia College of Pharmacists
Dr. David Fielding – Association of Faculties of Pharmacy of Canada

External Appointments

HRDC Sectoral Study of Pharmacists and Pharmacy Technicians

- Lt. Col. Régis Vaillancourt

NAPRA-CACDS e-Rx Task Force

- Jeff May
- Bill Veniot

National Initiative for Telehealth Guidelines

- Greg Eberhart

CPhA/CSHP National Task Force on Pharmacy Technicians

- Merv Blair

President's Report

H u g h E l l i s



OVER THE PAST TWELVE MONTHS, a number of NAPRA's core functions such as the operation of the National Drug Scheduling Advisory Committee and the maintenance of Canada's National Drug Scheduling System enjoyed continued broad support. NAPRA continued to support the operation of the Inter-provincial Pharmacy Regulatory Committee, which provided each Registrar and member licensing body with an important vehicle for communication on a broad range of current issues and for the sharing of ideas and solutions to both common and unique problems.

NAPRA has in the past year taken leadership positions in four specific areas, strongly demonstrating the intrinsic value of a strong national regulatory voice. These areas included:

- the negotiation of a licensing agreement for a Canadian version of the Verified Internet Pharmacy Practice Sites (VIPPS) program,
- the organization and hosting of the very successful February 2003 "Forum on the Export of Prescription Drugs to the US",
- the ongoing development of a National Continuing Competence Program Framework and,
- participation in the planning of the HRDC Pharmacy Manpower Sectoral Study.

These achievements, coupled with the ongoing day-to-day functions of communications, media relations, licensing issues, government liaison and professional exchange, serve to fill a busy agenda.

As the outgoing President I have two wishes for NAPRA.....

ONE – That the member licensing bodies will move forward on the priority list established by the Registrars early this year, and begin to work immediately on the issues of highest priority; and

TWO – That over the next 12 months, NAPRA Directors will make a commitment to increase communication between their national regulatory association and each member provincial regulatory authority. This includes an increased understanding of the issues and support required for national activities outside the established core functions.

I wish to thank NAPRA and the Board for the opportunity afforded me in allowing me to serve as President. It has been an experience I will continue to value as much as the friendships forged on the journey. I also wish to express my personal gratitude to both Barbara Wells and Louise Gaulin for their hours of service to NAPRA and their tolerance of my operating style. We were sad to lose Debbie Foran earlier this year but appreciate her many efforts, and wish her all the best in her new career.

Many thanks are also due to the Executive Committee for their support and guidance over the past year.

Executive Director's Report

B a r b a r a W e l l s

The past 12 months have been as usual, very busy ones for our Association. Over the 2002-2003 term, we welcomed Lt. Col. Régis Vaillancourt (Armed Forces), Burke Suidan (Alberta College of Pharmacists), Paul Tibbo (Nova Scotia College of Pharmacists), and Janet Zral (Yukon Government) to the NAPRA Board of Directors, but said farewell to Elsie Bagan, Sujay Khuroya, Jeff May, and Gladys Whyte.

The following is a summary of our primary accomplishments and activities over the past year.

DRUGS & DRUG SCHEDULING

Our Goal: To provide widely recognized national drug scheduling and scheduled drug advisory services that effectively complement the federal government's drug approval process in protecting the health and safety of the Canadian public. We are committed to ensuring that the scheduling process continues to be responsive, transparent, objective, and based on scientific principles. We strive to support our members in attaining scheduling by reference to Canada's National Drug Scheduling System and achieving full compliance with the conditions for sale of scheduled drugs.

Operation of the National Drug Scheduling Advisory Committee (NDSAC)

2002 was a record-breaking year for the Committee in terms of activity: 32 recommendations were made over the course of four live and three teleconference meetings. Dr. Marilyn Caughlin was elected Chairman and Dr.

Jeff Taylor, Vice-Chairman, and we welcomed three new Committee members: Dawn Frail (Nova Scotia), Dr. Larry Lynd (Ontario) and Fred Rumpel (Alberta), replacing Leanne Jardine and Janet Webb (whose terms of appointment expired), and Dr. Murray Brown (Ontario). Past-Chairman Dr. Colleen Metge's term of office also expired and a campaign to recruit her replacement is planned for 2003.

Maintenance of the National Scheduling System

The office continues to maintain communications with the 150 members of the *Drug Scheduling External Liaison Group*, to advise about upcoming scheduling amendments and drug scheduling news.

The Committee drafted revised scheduling factors to clarify their intent and improve usability. The revised draft factors have been pilot tested during the course of two meetings. We also initiated a review of the current submission criteria, originally developed in 1995. NDSAC's seven years of experience with submissions has provided new insight into the depth and scope of information needed to facilitate scheduling decisions. A report on the updated submission criteria is expected to be ready for stakeholder consultation in 2003.

Planning for the development of the drug product listing web-service linked to our national drug schedules was initiated. Provincial variances to the national schedules will be incorporated; the majority of these variances are temporary in nature and occur due to the time lapse between when the decisions are made and when the scheduling amendments are approved at the

provincial level (in the four member provinces without scheduling by reference). This new, expanded information service will improve consistency in the interpretation of the drug schedules and hopefully prove to be a valuable resource for pharmacists and pharmacy operators governed by NAPRA Members.

Of particular note this year was a report to our Board of Directors from NDSAC advising about international trends to move drugs traditionally prescribed by physicians to pharmacist-prescribed status, and the need for the profession to be ready to embrace the opportunities these changes will offer.

I made a presentation to the Non-Prescription Drug Manufacturers Association of Canada's Board of Directors on future trends in scheduling, met with delegations from a number of pharmaceutical companies regarding specific drugs, and presented an update on our scheduling processes to Therapeutic Product Programme (TPD) representatives. NDSAC Vice-Chairman Dr. Jeff Taylor also made a presentation on our behalf to the Council of the College of Pharmacists of BC last November, to provide an overview on how scheduling decisions are made.

Information about scheduled drugs

We participated in two Health Canada initiatives related to drug information: the product monograph revision project, and discussions on dissemination of drug safety information to health professionals.

The federal initiative to revise the official Drug Product Monograph is aimed at

highlighting clinically relevant information, making information easier to retrieve and consumer-focused, and improving consistency across different drugs and drug classes. Public access to reliable drug information is a long-standing issue of importance to NDSAC, and we have been following the government's progress in this area with interest.

I attended a Health Canada invitational workshop to explore ways to improve the manner in which drug safety information is disseminated to and used by, health professionals. This initiative will continue through 2003, and reinforces the importance of NAPRA's e-communication network as a means of transmitting drug safety information to pharmacists in a timely manner. Over the past 12 months we e-mailed 35 Health Canada and industry drug warnings directly to pharmacists in British Columbia, Manitoba, New Brunswick, Nova Scotia and PEI. To augment this member benefit, Lt. Col. Régis Vaillancourt developed an initial overall plan for NAPRA to create "pharmacist practice advisories" to accompany the Health Canada warning messages we disseminate. The aim of this project is to help pharmacists regulated by NAPRA members incorporate important drug safety information into their daily practices, so that the Canadian public can more consistently benefit from the warnings. This service will include a filtering mechanism to minimize the volume of warnings and information disseminated that is extraneous to pharmacy practice.

ISSUES MANAGEMENT

Our Goal: To identify and address emerging issues of importance to Canadian pharmacy regulators on a nationally coordinated basis, and in a pro-active, comprehensive and cost-effective manner.

Cross-border export of prescription drugs

The sale of prescription drugs from Canadian pharmacies to American patients has been a significant issue for a number of NAPRA members over the past 12 months. In February we hosted an invitational meeting of stakeholders from both countries to identify and clarify issues. Our “*Forum on the Export of Prescription Drugs to the US*” attracted 50 representatives from a vast range of interested parties. Participants’ feedback was overwhelmingly positive and NAPRA received recognition for its leadership in achieving reasoned discussion of what has been a controversial issue. NAPRA was subsequently represented at a meeting in Washington DC convened as a US-focused follow-up to our Forum, joining officials from the US Food and Drug Administration, the Drug Enforcement Agency and US Customs.

Subsequent to these meetings, NAPRA and NABP developed and endorsed a joint statement on the cross-border movement of prescriptions. The “*Cross Border Communiqué Regarding the International Movement of Prescription Drugs Between Canada and the United States*” signals the intentions of the two national regulatory associations to collaborate to support their Members in protecting the public.

Personal Information Protections and Electronic Documents Act (PIPEDA)

The Registrars have discussed the impact that this federal legislation could have on provincial operations. Last November our law firm provided the Council of Pharmacy Registrars of Canada with a comprehensive information and question-and-answer session specifically on this federal privacy legislation and its application to pharmacy. A proposal to provide pooled assistance to members in implementing this legislation is being considered.

Network of Regulatory Authorities (NORA)

I represented NAPRA at four NORA meetings during this reporting period. Of particular interest to us are the presentations and information sessions on federal initiatives to facilitate the settlement and enhanced integration of foreign-trained professionals into the Canadian workforce; standardized licensing terminology; continuing competence initiatives throughout self-regulated professions; and maintenance of the mutual recognition agreements established in 2001. Reports on the outcomes of these meetings have been prepared and provided to Members.

Canadian Coalition on Medication Incident Reporting and Prevention (CCMIRP)

NAPRA is a corresponding member of the Coalition, whose mandate includes the establishment of a medication incident and reporting system for Canada. The reporting system will be secure, anonymous and allow input from all health care delivery sites (including pharmacies, hospitals and even the patient’s home). Given the importance of the

information collected in setting standards of practice, drug scheduling matters and continuing competence, it is imperative that NAPRA Members have access to aggregate information and we will be following this project. In November, a letter of support in principle was sent on behalf of our Members for the proposed purpose, goals and key attributes of a medication incident reporting and prevention system as outlined by the Coalition.

Other

During this reporting period a number of other issues important to pharmacy regulators have been followed, including:

- Legalities regarding the sale of modafinil
- Prescription compounding. Alberta pharmacist Cathy Biggs represented NAPRA as a presenter at the US Pharmacopeia's "Compounding Stakeholders Forum" August 15.
- Non-medical use of drugs. Past President Jeff May and I represented NAPRA members' perspective during a presentation before the House of Commons Special Committee on Non-Medical Use of Drugs in August. We outlined the national drug schedules as a safety net for drug access and use, and the need for more Health Canada field enforcement support for our members, especially in the area of narcotics and sale of drugs through illegal on-line operations.
- Romanow Commission. In December I attended the "National Pharmacy Organizations Post-Romanow Workshop" hosted by the Canadian Pharmacists Association, on behalf of NAPRA. The purpose of the meeting was to explore the

feasibility of a common pharmacy response to the Commission's recommendations.


- Methadone maintenance. Last November, Dr. Brenda Osmond, Deputy-Registrar in BC, represented NAPRA at a Health Canada Multi-stakeholder Workshop on the Management of Drug Therapy in the Treatment of Opioids Dependence. The Ottawa conference was held as a consultation exercise on appropriate measures to manage the risks associated with drug therapies used in the treatment of opioids dependence, and on the review of the Methadone Control Program (MCP).

Mutual Recognition Agreement

A major issue under the auspices of the Registrars' group is maintenance of the Mutual Recognition Agreement. In accordance with a term of the original Agreement, NAPRA is facilitating a formal review of the Agreement amongst Signatories and non-Signatories, on behalf of our members. A survey was conducted in early 2003 for proposed improvements to the Agreement terms and amendments that could facilitate the participation of all provincial and territorial pharmacy licensing bodies, and CPRC will be reviewing the feedback. I have also maintained liaison with federal Human Resources Development Canada contacts on behalf of NAPRA Member Signatories, to outline our review process, specific issues arising with the Agreement, and funding possibilities.

Media Relations

The past 12 months were unprecedented in terms of national and international media exposure for NAPRA. This attention was almost



completely focused on the cross-border prescription trade issue, with some interest in the e-transmission of prescriptions, our VIPPS program, specialty certification, pharmacist malpractice liability, and the re-cycling of drugs. During this reporting period, NAPRA was represented in more than 50 interviews (including five televised) with a range of public media including: Bloomberg News, CBC National, CBC Newsworld, CBS News, CTV, FDA Consumer, Global Television, Globe and Mail, Los Angeles Times, Macleans, National Post, New York Times, Newsweek, Reuters, Wall Street Journal, and the Washington Post. NAPRA activities were also reported in professional journals such as the Canadian Medical Association Journal, Canadian Pharmaceutical Journal, Medical Post, Pharmacist Letter, and Pharmacy Post.

FEDERAL LEGISLATION AND INTERPRETIVE GUIDANCE

Our Goal: To provide an up-to-date, value-added online database of federal legislation, proposed federal regulatory amendments, and corresponding governmental and regulatory interpretive guidelines of relevance to pharmacists that will eliminate the need for members to maintain this service on a provincial basis.

We continue to monitor the status of all federal legislation of relevance to pharmacy regulators, to ensure that our posted versions of the Acts and Regulations are up-to-date. Over the course of this reporting period we kept NAPRA members apprised of the status of 17 specific proposed legislative amendments, and the development of “Precursor” regulations. One

particular achievement was the incorporation of drugs regulated under the *Controlled Drugs and Substances Act* into Schedule I into our National Drug Schedules.

LICENSING STANDARDS

Our Goal: To develop and maintain harmonized, up-to-date and fully implemented standards for initial licensing that meet the evolving needs of the Canadian public and reflect the changing role of pharmacists. We strive to assist our members to achieve a consistent and cost-effective implementation of these standards in support of the Agreement on Internal Trade, and to facilitate the entry of foreign-trained pharmacists into the Canadian workforce.

Competency-Based Standards of Practice (CBSOP)

During this reporting period, Competency-Based Standards of Practice (CBSOP) were developed and approved by the NAPRA Board. The success of this major initiative was due to the dedication of our CBSOP Working Group, the expertise of consultant Dr. Nancy Winslade, and input received through two national consultation exercises.

The CBSOP provide clarity on the range of situations in which pharmacists are expected to perform each competency element, as well as performance indicators to set out how well each must be performed. Two corollary documents were also developed and approved, presenting practice examples for each CBSOP and guidelines for exemplary or advanced practice. These documents will be distributed as the first revision of NAPRA's 1998 “*Model Standards of Practice for Canadian Pharmacists*”.

International Reciprocity for Pharmacists

Given the overlap between the accreditation criteria for American and Canadian pharmacy baccalaureate programs and apparent similarities in pharmacy practice, a decision was taken to explore international reciprocity arrangements with our neighbours to the south. Last July, a number of Registrars and I met by teleconference with staff of the National Association of Boards of Pharmacy to initiate negotiations for international reciprocity for pharmacists licensed by NABP and NAPRA members. Subsequently, a draft proposal from an external agency to compare licensing competencies and other requirements between our two countries has been circulated and is under review— a major first step to determine the feasibility of a reciprocity agreement.

HRDC Sectoral Study of Pharmacist and Pharmacy Technician Workforce

During this reporting period, Lt. Col. Régis Vaillancourt represented NAPRA at a number of meetings of the Study's Steering, Management, and Signatory committees. As one of three Signatories to the Study Incorporation Agreement, NAPRA is a key participant.

Centralized on-line licensing administration service

At the request of the Registrars, NAPRA staff presented two proposals to members of the Council of Pharmacy Registrars of Canada on the development and implementation of a centralized on-line licensing administration service. The goal of this project is to provide a cost-effective adjunct to the processes now in place in each licensing body. The proposals included the creation of a pharmacy portal, and pharmacycanada.com was secured as the URL for a future portal.

OPERATIONAL STANDARDS


Our Goal: To offer widely recognized standards and programs pertaining to operational aspects of Canadian pharmacies that will facilitate the optimal utilization of pharmacists as direct patient care providers and support the provision of safe and effective pharmacy services.

Optimal use of technology in the workplace

Bringing central fill and central processing technologies into Canadian pharmacy operations was under review by CPRC during most of this reporting period, as a possible factor in alleviating the demand for pharmacists in Canada. I visited two pharmacy central fill facilities in the US on behalf of the Registrars to observe this technology in action, and served as a regulatory resource for an external working group developing a proposal to allow for the implementation of central fill technology in Canada. The proposal was presented to the Registrars in November and received support in principle. Implementation will occur on a province-by-province basis.

Standards for the electronic transmission of prescriptions

Alberta College of Pharmacists Registrar Greg Eberhart represented NAPRA on the Canadian College of Health Service Executives' working group to develop telehealth guidelines. The "National Initiative for Telehealth Guidelines" project is funded through a grant from the Richard Ivey Foundation, and has as one of its primary objectives the development of a framework of national guidelines to be used by regulated health professionals in developing their specific standards and by telehealth providers as a benchmark for standards for service provisions.



Past-President Jeff May and New Brunswick Pharmaceutical Society Registrar Bill Veniot represent NAPRA on a joint CACDS-NAPRA e-Rx Task Force. The Task Force, co-chaired by Mr. May, is mandated to develop standards to allow for the electronic transmission of prescriptions between prescriber and pharmacist.

Verified Internet Pharmacy Practice Sites Program (VIPPS)

During this reporting period a number of versions of a NAPRA-NABP licensing agreement, Canadian criteria, verification processes for Canadian pharmacies, and corollary documents were developed, including a customized VIPPS Seal for Canada. In December 2002, both parties finally signed a Licensing Agreement that was mutually acceptable.

CONTINUING COMPETENCE

Our Goal: To facilitate the development and implementation of a harmonized, effective, regulatory program to ensure the continuing competence of practising pharmacists. NAPRA will strive to provide centralized assistance to members to achieve a consistent and cost-effective implementation of the program.

During this reporting period, our National Continuing Competence Program Core Steering Committee (NCCPCSC) was quite active in fulfilling its mandate to make recommendations to implement the National Continuing Competence Program Framework, approved by NAPRA's Board of Directors in 2000. Working in conjunction with consultant Dr. Nancy Winslade and under the chairmanship of Saskatchewan Pharmaceutical Association Registrar Ray Joubert, Committee members considered evaluation formats to assess practicing pharmacists' ability to meet the

Competency Based Standards of Practice. Emanating from this work was a decision to recommend that the previously approved Framework be revised, based on new information received on professional development and evaluation of professional competency worldwide, since 2000. Accordingly, a revised National Continuing Competence Model Program was presented and approved in principle by our Board in November, along with direction to proceed with planning for the recommended pilot projects, a national communication package to pharmacists, and a consultation exercise.

SPECIALTY CERTIFICATION

Our Goal: To create a national, voluntary regulatory program that facilitates the recognition of pharmacists with exemplary knowledge and skills in specific patient care areas. This centrally administered program will include competencies for each specialty practice area (built on the "Professional Competencies for Canadian Pharmacists at Entry-to-Practice"), assessment methodologies to evaluate candidates' achievement of the competencies, and a national registry service for those identified by NAPRA members as having met the competencies.

College of Pharmacists of British Columbia Registrar Linda Lytle has been leading this project on NAPRA's behalf over the past 12 months, through the College's "Advanced Practitioner Credentialing Committee". It is expected that the certification framework will include a practice review and knowledge assessment as evaluation tools. NAPRA's "Framework for Recognition of Pharmacy Specialties" was used as a basis for its development.

The National Institute for Standards in Pharmacist Credentialling's (NISPC) Disease State Management Examinations are being considered for adaptation and implementation in Canada through NAPRA and on recommendation by the BC College. We have recruited pharmacist content experts from a number of provinces in each of the three specialty areas to assess the examinations for relevance to Canadian pharmacists.

COMMUNICATIONS

Our Goal: To develop and maintain quality communication and outreach initiatives that effectively promote the activities and achievements of NAPRA and its Members to pharmacists, the public and other stakeholders.

NAPRA and PRA websites

In May we initiated training of licensing body staff members so that each can administer their province's own website content (hosted on the NAPRA website). Staff of the Manitoba Pharmaceutical Association, the New Brunswick Pharmaceutical Society, the Nova Scotia College of Pharmacists, PEI Board of Pharmacy, and Saskatchewan Pharmaceutical Association were trained during this reporting period.

To support traffic to our website, we agreed to serve as the code source for VICS EDI standards related to drug routes of administration and dosage forms, at the request of the ECCnet Pharmacy Users Group (a non-profit organization supporting business-to-business e-communication requirements).

E-Communication network/database

We purchased and installed a new robust e-mail software program in early December. Our Members in British Columbia, Manitoba, New

Brunswick, Nova Scotia and PEI use this web mail service to communicate directly with their members and we have provided technical support for provincial administrators. The national pharmacist/pharmacy database is updated on a monthly basis and this involves transforming each provincial data set into a format that is compatible with the central system. When each update is completed, new e-mail accounts for pharmacists are created in accordance with provincial Registers.

Corporate Representation

In addition to the specific meetings and events outlined above, NAPRA was represented at a number of corporate meetings during 2002 and early 2003 including the Canadian Pharmacists Association – NAPRA Executive Officers meeting; Board meeting of the Canadian Association of Pharmacy Students and Interns; Manitoba Pharmaceutical Association Council meeting and Annual General Meeting; the 5th Annual Chain Drug Conference hosted by CACDS; "Pharmacist Prescribing: Timely Benefit or Waste of Time" panel discussion at the Canadian Society of Hospital Pharmacists Western Branches Banff Seminar; and Therapeutic Products Directorate-NAPRA joint association meetings.

It has been truly a pleasure to work with members of NAPRA's Board of Directors, the Council of Pharmacy Registrars of Canada, and the various committees and working groups that we are involved with, over the past year. I would also like to especially acknowledge NAPRA Managers Louise Gaulin and Debbie Foran for their efforts on behalf of the Association through the past 12 months, and for their significant contributions to our achievements.



Auditors' Report

TO THE MEMBERS OF THE NATIONAL ASSOCIATION OF PHARMACY
REGULATORY AUTHORITIES

OTTAWA, Ontario
April 16, 2003

We have examined the non-consolidated balance sheet of the National Association of Pharmacy Regulatory Authorities as at December 31, 2002 and the non-consolidated statement of revenue and expense and equity for the year then ended. These financial statements are the responsibility of the Association's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the National Association of Pharmacy Regulatory Authorities, as well as evaluating the overall financial statement presentation.

In our opinion, these non-consolidated financial statements present fairly, in all material respects, the financial position of the Association as at December 31, 2002 and the results of its operations for the year then ended in accordance with generally accepted accounting principles except that they are prepared on a non-consolidated basis, as explained in Note 2.

Borth Gorton Schyns LLP

CHARTERED ACCOUNTANTS

NON-CONSOLIDATED BALANCE SHEET

As At December 31, 2002

	2002	2001
ASSETS		
CURRENT ASSETS		
Cash	\$ 17,298	\$ 1,151
Short-term investments – at cost (Market value \$139,900 – 2001 - \$160,052)	140,208	159,259
Accounts receivable	48,698	9,388
Prepaid expenses	5,907	698
Investment in wholly-owned subsidiary	–	18,925
	<u>212,111</u>	<u>189,421</u>
CAPITAL ASSETS		
Furniture and fixtures	23,642	20,200
Computer equipment and software	39,176	39,176
Leasehold improvement	4,250	4,250
	<u>67,068</u>	<u>63,626</u>
Less: Accumulated amortization	52,279	44,640
	<u>14,789</u>	<u>18,986</u>
	<u>226,900</u>	<u>208,407</u>
LIABILITIES AND MEMBERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable and accrued charges	\$ 90,456	\$ 37,166
MEMBERS' EQUITY		
	<u>136,444</u>	<u>171,241</u>
	<u>226,900</u>	<u>208,407</u>

SIGNED ON BEHALF OF
THE BOARD:



Counsellor



Counsellor

NON-CONSOLIDATED STATEMENT OF REVENUE AND EXPENSE AND EQUITY

For the Year Ended December 31, 2002

	2002 (Actual)	2002 (Budget)
REVENUE		
Membership fees	\$ 442,283	424,000
Special projects	41,040	-
Interest income	<u>3,339</u>	<u>3,000</u>
	486,662	427,000
EXPENSES		
Accounting and audit	5,969	5,000
Amortization	7,639	7,541
Communications	13,719	13,650
Drugs and drug scheduling	(22,137)	(35,265)
Governance	20,019	10,460
Insurance – O & D	1,465	1,400
Insurance – property	1,607	1,610
Interest and bank charges	803	700
IPRC – meetings	7,610	6,750
issues management	6,753	15,030
Legal – general	9,543	1,000
Licensing standards	16,973	15,600
Memberships and subscriptions	4,561	5,930
Miscellaneous	2,445	2,000
NSI – administration	13,514	10,000
NSI – licensing project	125,230	-
NSI – VIPPS	9,292	-
Office equipment	8,807	10,800
Office supplies	4,615	6,300
Operational standards	1,543	100
Postage – general	415	400
Practice standards	5,762	300
Professional development	42,782	47,300
Property maintenance and repairs	100	-
Rent	44,634	46,000
Salaries and benefits	179,238	209,343
Telephone	<u>8,558</u>	<u>10,000</u>
	521,459	391,959
NET REVENUE (EXPENSES) FOR THE YEAR	(34,797)	<u>35,041</u>
EQUITY, beginning of year	<u>171,241</u>	
EQUITY, end of year	<u>136,444</u>	

Notes to the Non-Consolidated

Financial Statements

For the Year Ended December 31, 2002

1. ORGANIZATION

The National Association of Pharmacy Regulatory Authorities is an incorporated not-for-profit organization which facilitates the national activities of provincial pharmacy regulatory authorities in their service of the public interest.

2. ACCOUNTING POLICIES

Accounting Presentation

The Canadian Institute of Chartered Accountants has recommended that financial statements prepared for issuance to members should be prepared on a consolidated basis except in the rare circumstances where this is not the more informative presentation. These financial statements, although they will be laid before the annual meeting of the members, have not been prepared on a consolidated basis.

The Association's investment in its subsidiary, is accounted for in the accompanying financial statements by the cost method under which the investment is carried at cost and the net earnings of the subsidiary company are reflected in the determination of the net earnings of the Association only to the extent of dividends received from the subsidiary.

In all other respects, these financial statements are in accordance with generally accepted accounting principles.

3. CAPITAL ASSETS

Capital assets are recorded at cost and are being amortized as follows:

Furniture and equipment	5 years	Straight-line
Computer equipment and software	4 years	Straight-line
Leasehold improvement	5 years	Straight-line

4. OPERATING LEASE

The Council leases its premises under an operating lease which expires November 30, 2005. Minimum lease payments for the next three fiscal years are as follows:

2003	\$21,070
2004	\$21,070
2005	\$19,314

5. INCOME TAX STATUS

The organization is exempt from income tax in Canada as a not-for-profit entity under Section 149(1)(L) of the *Income Tax Act (Canada)*.

6. BUDGET FIGURES

The budget figures are unaudited and are as provided by the Association's management.

7. COMPARATIVE FIGURES

Comparative figures are not provided on the statement of revenue and expense and equity because of a major realignment of the presentation of accounts for the year ended December 31, 2002 as compared to the year ended December 31, 2001.

NAPRA Member Contact Information

Alberta College of Pharmacists
10130–112th Street, 7th Floor
Edmonton, AB T5K 2K4
acpinfo@altapharm.org

College of Pharmacists of British Columbia
200–1765 West 8th Avenue
Vancouver, BC V6J 1V8
info@collegepharmacists.bc.ca

Manitoba Pharmaceutical Association
187 St. Mary's Road
Winnipeg, MB R2H 1J2
info@mpha.mb.ca

New Brunswick Pharmaceutical Society
Burbank Complex
101–30 Gordon Street
Moncton, NB E1C 1L8
nbphsbv@nbnet.nb.ca

Newfoundland Pharmaceutical Association
Apothecary Hall
488 Water Street
St. John's, NF A1E 1B3
npha@npha.nf.ca

Nova Scotia College of Pharmacists
P.O. Box 3363(S)
1526 Dresden Row
Halifax, NS B3J 3J1
nsps@ns.sympatico.ca

Prince Edward Island Pharmacy Board
South Shore Professional Building
Trans Canada Highway
Crapaud, PE C0A 1J0
peipharm@auracom.com

Saskatchewan Pharmaceutical Association
700–4010 Pasqua Street
Regina, SK S4S 7B9
saskpharm@sasktel.net

Government of the Northwest Territories
Health Professional Licensing
Health and Social Services
8th Floor, Centre Square Tower
Box 1320
Yellowknife, NT X1A 2L9
jeannette_hall@gov.nt.ca

Government of the Yukon
Registrar of Medical Practitioners
Justice Services Division
Box 2703
Whitehorse, YK Y1A 2C6
consumer@gov.yk.ca

Canadian Armed Forces
Medical Services Division
1745 Alta Vista Drive
Ottawa, ON X1A 2L9
vaillancourt.jrm@forces.ca